| Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B | Frank Vinluan | 11/25/19 | New York |
| New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.) | Alex Lash | 08/26/19 | National |
| MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms | Ben Fidler | 05/20/19 | New York |
| Matching Amgen, Regeneron to Cut List Price of Heart Drug by 60% | Ben Fidler | 02/11/19 | New York |
| 15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) | Ben Fidler | 12/18/18 | National |
| Amgen Slashes Cholesterol Drug Price 60% to Match Rival Regeneron | Frank Vinluan | 10/24/18 | National |
| Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More | Frank Vinluan | 09/14/18 | National |
| Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details | Ben Fidler | 05/11/18 | National |
| Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More | Ben Fidler | 05/04/18 | National |
| Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price | Ben Fidler | 05/01/18 | New York |
| Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & More | Frank Vinluan | 03/16/18 | National |
| Regeneron to Slash Price of Cholesterol Drug After Showing It Saved Lives | Ben Fidler | 03/10/18 | New York |
| Bio Roundup: Trump Health, Cholesterol Wars, 23andMe OK & More | Alex Lash | 03/09/18 | National |
| Esperion Touts Low Cholesterol Drug Price, But Not All Data are Ready | Alex Lash | 03/07/18 | Detroit Ann Arbor |
| Medicines Co. Sells Infectious Disease Drugs, Focusing on PCSK9 | David Holley | 11/29/17 | New York |
| 70% Repatha Cut? Amgen Counters With Own Study To Justify Price | Alex Lash | 08/23/17 | National |
| Amgen’s Heart Data Don’t Impress Drug-Price Evaluation Group | Alex Lash | 06/13/17 | San Francisco |
| The Medicines Co., Alnylam Take Plunge, Outline Big Test For Heart Drug | Ben Fidler | 04/26/17 | New York |
| FDA OKs Eczema Injection; Owners Regeneron, Sanofi Set $37K Price | Alex Lash | 03/28/17 | New York |
| With New Data, Amgen Promises Refund If Cholesterol Drug Doesn’t Work | Ben Fidler | 03/17/17 | San Francisco |
| Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M | Ben Fidler | 02/21/17 | Boston |
| Bio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More | Alex Lash | 02/10/17 | National |
| 14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/21/16 | National |
| Regeneron: It’s Still Wait Until 2017 For Big Heart Drug Study | Ben Fidler | 11/17/16 | New York |
| With New Data, Medicines Co. Takes Long-Lasting Heart Drug to Phase 3 | Ben Fidler | 11/15/16 | New York |
| In Cholesterol Drug Price Fight, Real Message Is “Wait Til Next Year” | Alex Lash | 08/18/16 | National |
| Intercept’s Liver Drug Wins FDA Approval To Treat Rare Disease | Alex Lash | 05/28/16 | New York |
| East Coast Biotech Roundup: NY Bio, Gender Gap, Zafgen, PureTech & More | Ben Fidler | 05/12/16 | Boston |
| Making the Price Right: Ideas To Change Drug Costs Gain Momentum | Alex Lash | 04/05/16 | National |
| East Coast Bio Roundup: PCSK9 Battle, NYU Startups, Blueprint & More | Ben Fidler | 03/17/16 | Boston |
